

To: (10)(2e) [(10)(2e) @rivm.nl]; (10)(2e) [(10)(2e) @rivm.nl]; (10)(2e) [(10)(2e) @rivm.nl]
From: (10)(2e)
Sent: Tue 7/21/2020 12:12:13 PM
Subject: RE: Gezondheidsraad report draft virology & clinical
Received: Tue 7/21/2020 12:12:19 PM
[DRAFT VIR CLIN Structure background document COVID_20072020 AV tk.docx](#)
[Rutten COVID verpleegtehuizen NTVGjuli2020.pdf](#)
[kolber changes Spike D614G Cell2020.pdf](#)

Hi (10)(2e)

I hope you don't mind but I have added some comments to the version of (10)(2e)

I send you a paper (published last week) in the Dutch journal of medicine. Although it is not in pubmed it still give I think valuable information about Dutch patients. This one is about old people in nursing homes.

And as reference for the long term sequela even for mild cases you could use the FMS- I included the link in the comments.

And you might consider to include something about the discussion of changes of the virus - and maybe being more transmitted or virulent?

(10)(2e)

From: (10)(2e) <(10)(2e)@rivm.nl>
Sent: dinsdag 21 juli 2020 11:17
To: (10)(2e) <(10)(2e)@rivm.nl>; (10)(2e) <(10)(2e)@rivm.nl>
Cc: (10)(2e) <(10)(2e)@rivm.nl>
Subject: Re: Gezondheidsraad report draft virology & clinical

hi (10)(2e)

I have added my part to the clinical chapter. I changed the order a bit and have added some references.

Could you update the document and put it in the R-files? I am working home without access to Endnote and R-files, so if you could help me this way?

Thanks! Any questions, let me know.

regards, (10)(2e)

From: (10)(2e)
Sent: Monday, 20 July 2020 17:16
To: (10)(2e); (10)(2e); (10)(2e)
Cc: (10)(2e)
Subject: Gezondheidsraad report draft virology & clinical

Dear (10)(2e)

Please find attached a first draft on the virology and clinical sections for the report to the Gezondheidsraad. I am also uploading a copy along with the Endnote files in the common folder:

(10)(2g)

© (10)(2e) could you please have a look and expand further/comment on the clinical section?

Additional information could be added regarding:

-prolonged infection and lasting symptoms reminiscent of chronic fatigue syndrome in some cases (any ideas on a good published reference on these?)

-re-infection (still in the domain of speculation, I haven't seen a publication with conclusive evidence)

-specifics of COVID-19 in children (I only mentioned Kawasaki-like disease in the paragraph on other sites) -> Shall we include children as a paragraph too, or will they be mentioned elsewhere in the report?

Comments and suggestions are more than welcome.

Kind regards,

(10)(2e)

(10)(2e)

European Public Health Microbiology (EUPHEM) (10)(2e)

National Institute for Public Health and Environment (RIVM)

Antonie van Leeuwenhoeklaan 9 | 3720 MA Bilthoven | The Netherlands

T (10)(2e)

E (10)(2e) @rivm.nl

I <http://www.rivm.nl>